1112 ECP Kira
BioCentury & Getty Images

Emerging Company Profile

Kira: overcoming the complexities of complement

Emerging Company Profile: Kira debuts with Beddingfield as CEO, three programs slated to enter clinic over 18 months

China-U.S. biotech Kira debuts with three programs for complement-mediated diseases and Frederick Beddingfield as its CEO.

Nov 13, 2020 | 3:50 AM GMT

Cross-border biotech Kira is developing therapeutics for complement-mediated cancer and inflammatory and autoimmune diseases that address the mechanistic and PK challenges of targeting the complement pathway. 

Kira Pharmaceuticals Ltd. was founded in 2017 by Chairman, President and

Read the full 876 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE